A book of companies defining the future of the human condition.

An operator-led founding team executing factory build-outs at a tempo that incumbents cannot match. A structural cost advantage rooted in the input chemistry, not in marketing positioning. A long-term play on American manufacturing reindustrialization that compounds with each production line that comes online.

A founder with the conviction to fund hundreds of millions of dollars of his own capital through R&D. Alignment is total. A two-year hardware lead in a category where physics, not narrative, decides the winner. Hard, regulated, capital-intensive infrastructure with a defined re-rating moment as the post-ISS commercial era begins. Patient capital is exactly the right capital here.

Founder caliber and scientific vision validated through years of close-quarters relationship. A defensible position in a real, contested category, where a well-engineered platform manufactured in Asia with active US distribution can take share against incumbents. Direct alignment with our life-sciences thesis: the same pharma, biotech, CRO, CDMO, and research accounts our operating partner already supplies are the natural buyers for CytoSpark and OMNIdrop instruments.

Two technically credible founders covering the two hardest surfaces of the product: signal processing and inference. Engineering rigor and a cognitive profile we trust to compound. A category that defines a future mode of human-machine interaction.

A founding team with prior exits in the same category, recruited entirely on reputation. Unique IP that defines a defensible position in a market the incumbents physically cannot serve. A long-term scientific bet on a problem the rest of the industry has left unsolved, backed by a credible, milestone-gated technical plan.